Related Experiment Video
Updated: Apr 29, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.0K
Caregiver burden in mild cognitive impairment
Matt Paradise1, Donna McCade, Ian B Hickie
1a Brain & Mind Research Institute, University of Sydney , Camperdown , Australia.
Aging & Mental Health
|May 29, 2014
Summary
Caregiver burden is high in mild cognitive impairment (MCI), with 36% reporting significant distress. Patient behavioral issues and depression are key factors contributing to this burden.
Area of Science:
- Neurology
- Gerontology
- Psychiatry
Background:
- Mild cognitive impairment (MCI) affects a significant portion of the aging population.
- Caregiver burden is a recognized issue in neurodegenerative diseases.
- Understanding caregiver burden in MCI is crucial for developing support strategies.
Purpose of the Study:
- To compare caregiver burden in mild cognitive impairment (MCI) versus a control group.
- To identify factors associated with caregiver burden in MCI.
- To explore patient and caregiver characteristics linked to significant burden.
Main Methods:
- Cross-sectional study design.
- Recruited 64 MCI participants, 36 controls, and their caregivers.
- Assessed burden using Zarit Burden Interview score (>21).
- Analyzed associations between participant/caregiver characteristics and burden using multivariate analyses.
Main Results:
- 36% of MCI caregivers reported clinically significant burden, double the rate of controls.
- Participant behavioral problems were the primary contributor to caregiver burden.
- Participant depression and cognitive status also showed significant associations with burden.
Conclusions:
- Caregiver burden is a substantial issue in MCI.
- Patient behavioral challenges are strongly linked to caregiver burden, similar to dementia.
- Findings inform future research and interventions for MCI caregivers.
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:30Dementia
686
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
686
01:29Alzheimer Disease l: Introduction
20
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
01:23Alzheimer Disease ll: Pathophysiology
32
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32
01:22Dementia l: Introduction
31
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
31
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K